NCT04632758 2023-11-24
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
Clinical Trials
3 trialsNCT05204628 2022-01-24
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04009317 2019-10-30
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown